Comparative Pharmacology
Head-to-head clinical analysis: BAYCOL versus PITAVASTATIN CALCIUM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BAYCOL versus PITAVASTATIN CALCIUM.
BAYCOL vs PITAVASTATIN CALCIUM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cerivastatin is a competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme in cholesterol biosynthesis, thereby reducing hepatic cholesterol production and increasing LDL receptor expression.
Competitive inhibitor of HMG-CoA reductase, reducing cholesterol synthesis in the liver and increasing LDL receptor expression.
Cervastatin 0.4 mg orally once daily in the evening, with or without food.
1-4 mg orally once daily
None Documented
None Documented
2-4 hours (terminal elimination half-life); clinical context: supports twice-daily dosing
The terminal elimination half-life is approximately 12 hours (range 9–16 hours), supporting once-daily dosing.
Renal: ~70% (mostly as unchanged drug); fecal: ~15%
Approximately 79% of the dose is excreted in feces (as parent drug and metabolites) via biliary elimination, and about 15% is excreted in urine. Less than 2% is excreted unchanged in urine.
Category C
Category D/X
Statin
Statin